Ontology highlight
ABSTRACT:
SUBMITTER: Wu X
PROVIDER: S-EPMC9902866 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
Wu Xinyu X Chau Yi Fung YF Bai Hua H Zhuang Xiaofei X Wang Jie J Duan Jianchun J
Frontiers in oncology 20230124
Immune checkpoint inhibitors (ICIs) are highly concerned in the treatment of non-small cell lung cancer (NSCLC), represented by inhibitors of programmed death protein 1 (PD-1) and its ligand (PD-L1), and inhibitors of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The introduction of immunotherapy in the treatment of perioperative NSCLC has improved the prognosis to a great extent, as demonstrated by several phase II and III clinical trials. The target population for immunotherapy in earl ...[more]